Therefore the applicant does not have the burden of proof to show efficacy in the revocation of a marketing authorisation; 2. that there has been either insufficient or no justification of alleged harmful effects of Naftidrofuryl; 3. that modern biometric techniques cannot be used to prove the efficacy of Naftidrofuryl.